Testing this therapy on human glioblastoma cell lines and xenografts, they showed that the addition of anti-CD47 led to increased tumor-cell phagocytosis in both M1 and M2 macrophages, but this increase was more prominent in M1 macrophages [60]. This evidence concerns the gene CD47 and neoplasm.